| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2826.2005.01337.X |
| P8608 | Fatcat ID | release_iveklhf5onc3hohpmmtqndws3e |
| P698 | PubMed publication ID | 16011487 |
| P2093 | author name string | Morin N | |
| Di Paolo T | |||
| Morissette M | |||
| Jourdain S | |||
| P2860 | cites work | Expression and neuropeptidergic characterization of estrogen receptors (ERalpha and ERbeta) throughout the rat brain: anatomical evidence of distinct roles of each subtype | Q48397592 |
| Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system | Q48590882 | ||
| Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia, and excitatory amino acids in murine cortical cultures | Q48643598 | ||
| Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain | Q48696024 | ||
| Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. | Q51006160 | ||
| Brain dopamine transporter: gender differences and effect of chronic haloperidol. | Q51044944 | ||
| Dendrite loss is a characteristic early indicator of toxin-induced neurodegeneration in rat midbrain slices. | Q52538112 | ||
| Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. | Q53236382 | ||
| Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta | Q28304508 | ||
| Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study | Q28369296 | ||
| The effect of estrogen replacement on early Parkinson's disease | Q33607692 | ||
| Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons | Q33828029 | ||
| Neuroprotective effects of estrogens: potential mechanisms of action | Q33922344 | ||
| Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. | Q33925972 | ||
| Neuroprotection by estradiol. | Q34065270 | ||
| Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury | Q34114102 | ||
| Production and actions of estrogens | Q34513002 | ||
| Anti-oxidative neuroprotection by estrogens in mouse cortical cultures | Q34656829 | ||
| Dopamine agonists and neuroprotection in Parkinson's disease | Q35015790 | ||
| Immunolocalization of Estrogen Receptor β in the Mouse Brain: Comparison with Estrogen Receptor α | Q40655085 | ||
| Parkinson's disease. Second of two parts | Q40840040 | ||
| Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice | Q43635677 | ||
| Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community | Q44436066 | ||
| Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias | Q45711922 | ||
| Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones | Q47963248 | ||
| P433 | issue | 8 | |
| P921 | main subject | substantia nigra | Q753278 |
| P304 | page(s) | 509-517 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Journal of Neuroendocrinology | Q3186929 |
| P1476 | title | Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice | |
| P478 | volume | 17 |
| Q42705523 | Age-dependent dopaminergic dysfunction following fetal exposure to atrazine in SD rats |
| Q42512645 | Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys |
| Q28572108 | Effect of zinc and paraquat co-exposure on neurodegeneration: Modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats |
| Q35539953 | Estrogen receptor beta expression in the embryonic brain regulates development of calretinin-immunoreactive GABAergic interneurons. |
| Q34437648 | Formulations of hormone therapy and risk of Parkinson's disease |
| Q37721503 | Genes, Gender, Environment, and Novel Functions of Estrogen Receptor Beta in the Susceptibility to Neurodevelopmental Disorders. |
| Q35972056 | Male/Female differences in neuroprotection and neuromodulation of brain dopamine |
| Q48283898 | Minocycline Rescues from Zinc-Induced Nigrostriatal Dopaminergic Neurodegeneration: Biochemical and Molecular Interventions |
| Q37467662 | Neuroprotective actions of sex steroids in Parkinson's disease |
| Q34168229 | No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease |
| Q37905899 | Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease |
| Q34483979 | Oestrogen receptors enhance dopamine neurone survival in rat midbrain |
| Q35889761 | Polymorphism in the Vesicular Monoamine Transporter 2 Gene Decreases the Risk of Parkinson's Disease in Han Chinese Men. |
| Q50534763 | Sex-Dependent Changes in Striatal Dopamine Transport in Preadolescent Rats Exposed Prenatally and/or Postnatally to Methamphetamine. |
| Q37990324 | Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease |
| Q37765941 | Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders |
| Q37845675 | The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease |
| Q90077289 | The role of G protein-coupled estrogen receptor 1 on neurological disorders |
Search more.